<p>西雅图，2025 年 12 月 09 日（全球新闻通讯社）——Adaptive Biotechnologies Corporation（纳斯达克：ADPT）是一家商业阶段的生物技术公司，旨在将适应性免疫系统的遗传学转化为临床产品，以诊断和治疗疾病。今天宣布，首席科学官兼联合创始人哈兰·罗宾斯博士和首席商业官苏珊·博布尔斯基将参加杰富瑞的炉边谈话，讨论血液学/肿瘤学中的最小残留病（MRD），并深入探讨 clonoSEQ 检测技术。此次电话会议将于 2025 年 12 月 11 日（星期四）东部时间下午 2:00 至 3:00 举行。有兴趣的各方可以联系他们的杰富瑞销售代表以获取详细信息。</p>
<p><strong>关于 Adaptive Biotechnologies</strong></p>
<p>Adaptive Biotechnologies（“我们” 或 “我们的”）是一家商业阶段的生物技术公司，专注于利用适应性免疫系统的固有生物学来转变疾病的诊断和治疗。我们相信，适应性免疫系统是自然界对大多数疾病最精细的诊断和治疗工具，但解码能力的缺乏使医学界无法充分利用其潜力。我们的专有免疫医学平台以规模、精度和速度揭示并转化适应性免疫系统的庞大遗传信息。我们将我们的平台应用于与生物制药公司合作，提供药物开发信息，并在最小残留病（MRD）和免疫医学两个业务领域开发临床诊断。我们的商业产品和临床管道使得能够诊断、监测和治疗癌症及自身免疫性疾病等疾病。我们的目标是开发和商业化针对每位患者量身定制的免疫驱动临床产品。</p>
<p><strong>适应性投资者</strong></p>
<p>卡里娜·卡尔萨迪拉，投资者关系及财务规划与分析副总裁</p>
<p>201-396-1687</p>
<p>investors@adaptivebiotech.com</p>
<p><strong>适应性媒体</strong></p>
<p>埃里卡·琼斯，企业传播副总监</p>
<p>206-279-2423</p>
<p>media@adaptivebiotech.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UWTVOQ00zTXpFME5UYzRJekl4TnpjeE9EST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UWTVOQ00zTXpFME5UYzRJekl4TnpjeE9EST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjcxMGZkYjMtMmYyYS00ZTEyLTk5MmMtNmE2Y2FjMTc4ZDcwLTExODg3NTItMjAyNS0xMi0wOS1lbg==/tiny/Adaptive-Biotechnologies.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjcxMGZkYjMtMmYyYS00ZTEyLTk5MmMtNmE2Y2FjMTc4ZDcwLTExODg3NTItMjAyNS0xMi0wOS1lbg==/tiny/Adaptive-Biotechnologies.png"/></p>

ADPT

<p>Adaptive Biotechnologies 将于 2025 年 12 月 11 日参加 Jefferies 的炉边谈话，讨论血液学/肿瘤学中的微小残留病（MRD）和 clonoSEQ 检测技术。Harlan Robins 博士和 Susan Bobulsky 将代表公司出席。Adaptive Biotechnologies 专注于通过适应性免疫系统转变疾病的诊断和治疗。该活动对有兴趣的各方开放，参与者可以通过 Jefferies 的销售代表进行联系</p>

<p>SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced Dr. Harlan Robins, Chief Scientific Officer and Co-Founder and Susan Bobulsky, Chief Commercial Officer, MRD will be participating in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology with deep dive into the clonoSEQ assay technology. The call will take place on Thursday, December 11, 2025, from 2:00 p.m. to 3:00 p.m. Eastern Time. Interested parties may reach out to their Jefferies sales representative for details.</p>
<div class="lb-trans"><p>西雅图，2025 年 12 月 09 日（全球新闻通讯社）——Adaptive Biotechnologies Corporation（纳斯达克：ADPT）是一家商业阶段的生物技术公司，旨在将适应性免疫系统的遗传学转化为临床产品，以诊断和治疗疾病。今天宣布，首席科学官兼联合创始人哈兰·罗宾斯博士和首席商业官苏珊·博布尔斯基将参加杰富瑞的炉边谈话，讨论血液学/肿瘤学中的最小残留病（MRD），并深入探讨 clonoSEQ 检测技术。此次电话会议将于 2025 年 12 月 11 日（星期四）东部时间下午 2:00 至 3:00 举行。有兴趣的各方可以联系他们的杰富瑞销售代表以获取详细信息。</p>
</div><p><strong>About Adaptive Biotechnologies</strong></p>
<div class="lb-trans"><p><strong>关于 Adaptive Biotechnologies</strong></p>
</div><p>Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.</p>
<div class="lb-trans"><p>Adaptive Biotechnologies（“我们” 或 “我们的”）是一家商业阶段的生物技术公司，专注于利用适应性免疫系统的固有生物学来转变疾病的诊断和治疗。我们相信，适应性免疫系统是自然界对大多数疾病最精细的诊断和治疗工具，但解码能力的缺乏使医学界无法充分利用其潜力。我们的专有免疫医学平台以规模、精度和速度揭示并转化适应性免疫系统的庞大遗传信息。我们将我们的平台应用于与生物制药公司合作，提供药物开发信息，并在最小残留病（MRD）和免疫医学两个业务领域开发临床诊断。我们的商业产品和临床管道使得能够诊断、监测和治疗癌症及自身免疫性疾病等疾病。我们的目标是开发和商业化针对每位患者量身定制的免疫驱动临床产品。</p>
</div><p><strong>ADAPTIVE INVESTORS</strong></p>
<div class="lb-trans"><p><strong>适应性投资者</strong></p>
</div><p>Karina Calzadilla, Vice President, Investor Relations and FP&amp;A</p>
<div class="lb-trans"><p>卡里娜·卡尔萨迪拉，投资者关系及财务规划与分析副总裁</p>
</div><p>201-396-1687</p>
<div class="lb-trans"><p>201-396-1687</p>
</div><p>investors@adaptivebiotech.com</p>
<div class="lb-trans"><p>investors@adaptivebiotech.com</p>
</div><p><strong>ADAPTIVE MEDIA</strong></p>
<div class="lb-trans"><p><strong>适应性媒体</strong></p>
</div><p>Erica Jones, Associate Corporate Communications Director</p>
<div class="lb-trans"><p>埃里卡·琼斯，企业传播副总监</p>
</div><p>206-279-2423</p>
<div class="lb-trans"><p>206-279-2423</p>
</div><p>media@adaptivebiotech.com</p>
<div class="lb-trans"><p>media@adaptivebiotech.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UWTVOQ00zTXpFME5UYzRJekl4TnpjeE9EST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5OTY5NCM3MzE0NTc4IzIxNzcxODI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjcxMGZkYjMtMmYyYS00ZTEyLTk5MmMtNmE2Y2FjMTc4ZDcwLTExODg3NTItMjAyNS0xMi0wOS1lbg==/tiny/Adaptive-Biotechnologies.png" alt="" original-src="https://ml.globenewswire.com/media/ZjcxMGZkYjMtMmYyYS00ZTEyLTk5MmMtNmE2Y2FjMTc4ZDcwLTExODg3NTItMjAyNS0xMi0wOS1lbg==/tiny/Adaptive-Biotechnologies.png"/></p>

Adaptive Biotechnologies 将参与 Jefferies 炉边谈话系列，讨论微小残留病 | ADPT 股票新闻